Rituxan Hycela Injection, Solution
Product Images NDC 50242-108

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rituxan Hycela (NDC 50242-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (11.7 mL Vial Carton)

Rituxan Hycela injection label showing the combination of rituximab and hyaluronidase human for subcutaneous use. The vial contains 1,400 mg of rituximab and 23,400 Units of hyaluronidase in 11.7 mL (120 mg and 2,000 Units per mL). The label specifies single-dose vial usage and medication guide dispensing, with Genentech, Inc. and Biogen logos present.*

FDA Label Image

Principal Display Panel (13.4 mL Vial Carton)

Label for Rituxan Hycela injection, a subcutaneous solution combining rituximab and hyaluronidase human. The vial contains 1,600 mg rituximab and 26,800 Units hyaluronidase in 13.4 mL (equivalent to 120 mg and 2,000 Units/mL). The label indicates single-dose use and instructs subcutaneous administration over 5 to 7 minutes. Labeler information includes Genentech, Inc. and Biogen.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.